Back to Search
Start Over
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
- Source :
-
Breast cancer (Tokyo, Japan) [Breast Cancer] 2020 May; Vol. 27 (3), pp. 389-398. Date of Electronic Publication: 2019 Dec 06. - Publication Year :
- 2020
-
Abstract
- Background: Assessing survival risk is important for discussing treatment options with estrogen receptor-positive (ER+) advanced breast cancer (ABC) patients. However, there are few reports from large-scale databases on the survival risk factors in ER+ ABC. The Safari study (UMIN000015168) was a retrospective, multicenter cohort study involving 1072 Japanese patients receiving fulvestrant 500 mg mostly as a second- or later-line endocrine therapy for ER+ ABC. The follow-up data after the Safari study were examined, focusing on any relationship between clinicopathological factors and overall survival (OS) in ER+ ABC patients.<br />Methods: OS in patients with ER+ ABC was analyzed by univariate and multivariate analyses with a Cox proportional hazards model in this study.<br />Results: A total of 1031 cases were evaluable for OS analysis. Multivariate analysis showed that younger age (< 60 years), longer time from ABC diagnosis to fulvestrant use (≥ 3 years), no prior palliative chemotherapy before fulvestrant use, and progesterone receptor (PgR) negativity (PgR-) were significantly correlated with prolonged OS (median 7.0 years). For cases with histological or nuclear grade data, lower histological or nuclear grades were also correlated with longer OS. In recurrent metastatic cases, long disease-free interval (DFI) was not correlated with longer OS.<br />Conclusions: In ER+ ABC patients whose treatment history included fulvestrant, younger age, longer time from ABC diagnosis to fulvestrant use, no prior palliative chemotherapy use, PgR-, and lower histological or nuclear grade correlated positively with prolonged OS.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal therapeutic use
Breast Neoplasms drug therapy
Breast Neoplasms pathology
Carcinoma, Ductal, Breast drug therapy
Carcinoma, Ductal, Breast pathology
Carcinoma, Lobular drug therapy
Carcinoma, Lobular pathology
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Recurrence, Local drug therapy
Neoplasm Recurrence, Local pathology
Prognosis
Receptor, ErbB-2 metabolism
Receptors, Estrogen metabolism
Receptors, Progesterone metabolism
Retrospective Studies
Survival Rate
Breast Neoplasms mortality
Carcinoma, Ductal, Breast mortality
Carcinoma, Lobular mortality
Fulvestrant therapeutic use
Neoplasm Recurrence, Local mortality
Postmenopause
Subjects
Details
- Language :
- English
- ISSN :
- 1880-4233
- Volume :
- 27
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Breast cancer (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 31811519
- Full Text :
- https://doi.org/10.1007/s12282-019-01029-3